Cencora, IncNYSE: COR
Health Care · Health Care Distributors
$305.04
-0.96%
Vol: 1.5M
Research Digest
Friday, May 1, 2026
Cencora Q2 earnings May 6 with 8.8% EPS growth expected; pursues $1.1B retina services acquisition.
Cencora gearing up for Q2 earnings May 6, 2026, with expectations for 8.8% EPS growth to $4.81 and revenue $80.76B. Wells Fargo issued Buy rating April 13. Announced $1.1B acquisition of EyeSouth Retina Business to expand healthcare solutions and definitive merger with Covetrus and MWI Animal Health to create integrated animal health platform valued $3.5B. Despite recent downward revisions and Zacks Rank #4 sell, shows strong shareholder returns of 51.29% one-year and 265.50% five-year.
Previous Market Intelligence
13 daysApr 30Cencora announced $1.1B retina business acquisition and merger with Covetrus/MWI Animal Health to expand specialty services.Positive▶
Cencora reported strong Q1 FY2026 results with revenue of $85.9B (+5.5% YoY) and adjusted EPS of $4.08 (+9.4% YoY). The company is expanding its specialty services through a $1.1 billion acquisition in the retina business and announced a definitive merger agreement with Covetrus and MWI Animal Health, valuing MWI at an enterprise value of $3.5 billion. CFO James Cleary will retire after 7.5 years. The company priced a $3.0 billion debt offering. Earnings report scheduled for May 6.
Apr 16Cencora to release Q2 2026 earnings May 6; CFO James Cleary retiring June 30Neutral▶
Cencora announced CFO James Cleary will retire effective June 30, 2026. The company will release Q2 FY2026 results on May 6, 2026 before market open. Recent investor activity includes State of Alaska reducing position by 34.5% in Q4. Stock down 8% last month but up 51.29% over one year.
Apr 15Cencora maintains upside potential despite recent weakness; CFO retirement announced with guidance reaffirmed.Neutral▶
Cencora is set to report Q2 2026 results on May 6. The company announced CFO James Cleary's retirement on March 17, with financial guidance reaffirmed. Q1 2026 EPS of $4.08 beat estimates. Evercore ISI Group lowered its price target from $420 to $360 on April 8 while maintaining Outperform rating. Recent acquisitions include EyeSouth Partners' retina business for $1.1 billion. Stock is down 8% over the past month.
Apr 14Cencora faces analyst caution with Evercore lowering price target amid valuation pressure and mixed recent performance.Mixed▶
Cencora reported share weakness with stock down ~8% over past month. Evercore ISI lowered target from $420 to $360 maintaining Outperform. Q2 2026 earnings scheduled for May 6. Analysts view COR as strong buy based on solid fundamentals, consistent dividend growth, and A-level credit rating. Stock near $325.
Apr 13Cencora completes $3 billion senior notes offering and advances healthcare acquisitions including $1.1 billion EyeSouth retina division deal.Positive▶
Cencora raised $3 billion through a five-tranche senior notes offering to fund strategic healthcare expansion. The company is acquiring EyeSouth's retina division for $1.1 billion. CFO James Cleary will retire June 30, 2026. Analysts maintain a consensus Buy rating with an average 12-month price target of $395.23 (+21.68% upside).
Apr 10Cencora lowers analyst price target to $360 while expanding ophthalmology reach with $1.1B EyeSouth retina acquisition.Mixed▶
Evercore ISI Group lowered Cencora price target to $360 from $420 on April 8, though maintaining Outperform rating. Cencora announced a $1.1 billion acquisition of EyeSouth retina division to enhance its Retina Consultants of America network. The company reaffirmed fiscal 2026 earnings guidance. Stock trading near $324.93 with next earnings report expected May 6.
Apr 9Cencora continues M&A expansion with OneOncology acquisition momentum and strong specialty pharma demand.Positive▶
Cencora beat Q1 estimates driven by specialty medicines and GLP-1 therapy demand. The company raised long-term guidance reflecting OneOncology acquisition, with fiscal 2026 guidance reaffirmed. Recently expanded into ophthalmology with $1.1B EyeSouth retina acquisition and formed merger with Covetrus to create integrated animal health platform valued at $3.5B enterprise value. 13 analysts rate stock "Buy" with $395.23 price target, 21.7% upside.
Apr 8Cencora Acquires EyeSouth Retina Division for $1.1B; Expands Healthcare PortfolioPositive▶
Cencora signed binding agreement to acquire EyeSouth retina division for $1.1B, expanding Retina Consultants network. Stock up 0.34% with positive long-term outlook despite recent monthly decline of -13.60%.
Apr 7Cencora announces $1.1B EyeSouth retina acquisition and schedules Q2 FY26 earnings for May 6Positive▶
Cencora announced definitive agreement to acquire EyeSouth Partners' retina business for $1.1B on March 23. Deal expected slightly accretive to adjusted diluted EPS in first 12 months. CFO James Cleary retiring June 30, 2026. Q2 FY26 earnings May 6. Q1 FY26 showed revenue +5.5% YoY at $85.9B and adjusted diluted EPS +9.4% YoY at $4.08.
Apr 6Cencora announces $1.1B EyeSouth retina acquisition and strong revenue growth trajectory.Positive▶
Cencora announced binding agreement to acquire EyeSouth's retina division for $1.1B, expanding its healthcare distribution capabilities through Retina Consultants of America. Fiscal 2025 revenue was $321.33B (up 9.31%), with earnings up 2.99%. CFO James F. Cleary retiring June 30, 2026. Q2 FY2026 earnings scheduled for May 6, 2026. Analyst consensus rates COR as Buy with 12-month price target of $395.23 (21.68% upside). Stock price at $322.44 with 51.29% one-year total return demonstrating strong shareholder value creation.
Apr 3Cencora acquires EyeSouth retina business for $1.1B and merges MWI Animal Health with Covetrus in $3.5B deal.Positive▶
Cencora announced binding agreement to acquire EyeSouth Partners' retina business for $1.1 billion, expanding its healthcare delivery network. COR will merge MWI Animal Health unit with Covetrus in transaction valuing MWI at $3.5 billion enterprise value. CFO James Cleary announced retirement effective June 30. Q2 FY2026 earnings scheduled for May 6.
Apr 2Cencora acquires EyeSouth Partners for $1.1B; Q2 earnings May 6Positive▶
Cencora acquires EyeSouth Partners' retina business for $1.1 billion; Q2 fiscal 2026 earnings scheduled for May 6, 2026.
Apr 1Cencora signs definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion.Positive▶
Cencora announced a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion, expanding specialty healthcare services. CFO James Cleary announced his retirement. Fiscal year 2026 Q1 revenue increased 5.5% YoY to $85.9 billion. Analysts maintain Buy consensus with PT of $395.23.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| MCKMCKESSON | $815.42 | +0.03% | -4.8% | 18.5x | 0.42 | $99.9B |
| CORCENCORA | $305.04 | -0.96% | -4.0% | 15.7x | 0.72 | $59.9B |
| CAHCARDINAL | $195.26 | +1.23% | -9.3% | 16.6x | 0.65 | $45.4B |
| HSICHENRY | $74.09 | -0.68% | -0.4% | 12.7x | 0.88 | $8.6B |
| LLYELI | $964.50 | +3.20% | +0.8% | 22.2x | 0.50 | $834.9B |
| JNJJOHNSON | $227.78 | -0.90% | -4.6% | 18.1x | 0.33 | $553.3B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.